Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: GlobalData
Provider: New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Hologic Inc Issues Q2 2013 Guidance Below Analysts' Estimates; Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance

Monday, 4 Feb 2013 04:01pm EST 

Hologic Inc announced that for the second quarter of 2013, it expects non-GAAP adjusted revenues of $635 million to $640 million (excludes an expected purchase accounting reduction of $5.2 million related to the Novartis collaboration). The increase is driven primarily by the inclusion of revenues related to the Gen-Probe acquisition, the continued ramp-up of new products including the Dimensions, PANTHER, and MyoSure systems and an expected overall improvement in each of the Company's operating segments, partially offset by an elimination in Adiana system revenues and revenues associated with LIFECODES which is expected to be sold during the quarter and expects non-GAAP adjusted EPS of $0.33 to $0.34. This reflects the expected benefit of approximately $0.01 from the recently-reinstated federal research tax credit, the expected impact of the medical device excise tax which is to be $0.02 dilutive. For fiscal 2013, the Company is reaffirming its non-GAAP adjusted revenues of $2.61 billion to $2.64 billion and expects non-GAAP adjusted EPS of $1.58 to $1.60. This is $0.02 higher than the guidance provided on November 12, 2012 due to the recently-reinstated federal research tax credit, partially offset by a slight increase in expected operating expenses. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $650 million and EPS of $0.38 for the second quarter of 2013; revenues of $2.63 billion and EPS of $1.58 for fiscal 2013. 

Company Quote

-0.03 -0.11%
19 Dec 2014